-+ 0.00%
-+ 0.00%
-+ 0.00%

Hanson Pharmaceuticals (03692): The marketing license application for injectable HS-20093 treatment for small cell lung cancer was accepted by the State Drug Administration

Zhitongcaijing·09/02/2026 08:41:14
Listen to the news

According to Zhitong Finance App, Hanson Pharmaceuticals (03692) announced that on September 2, 2026, the Group's innovative drug HS-20093 marketing license application for injectable use was accepted by the China National Drug Administration (NMPA) to treat adult patients with small cell lung cancer (SCLC) who have previously failed platinum-containing treatment. HS-20093 for injection is a B7-H3 targeting antibody-drug conjugate (ADC) independently developed by the Group.